# A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3

> **NCT00002129** · PHASE1 · COMPLETED · sponsor: **Otsuka America Pharmaceutical** · enrollment: 36 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Vesnarinone

## Key facts

- **NCT ID:** NCT00002129
- **Lead sponsor:** Otsuka America Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 36 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002129, "A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*